The Lancet Gastroenterology & Hepatology Commission_Cooke, Graham

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

The Global Review Update on 25 National Profiles_Ward, John

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

The Global Fund_Abdelfadil, Lee

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

The Bangladeshi National Program on Hepatitis Elimination_Shwapnil, Mamun Al-Mahtab

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

Status of the HBV Functional Cure and the Role of Testing_Dusheiko, Geoffrey

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

Patient Perspective on HBV Treatment & Cure_Adda, Danjuma K.

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

New Global Initiatives_Mohammed, Abdulaziz

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

Hepatitis Zero Program in Brazil and Africa_Silva, Humberto

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

Diagnosis Impact of Stigma on Diagnosis of Hepatitis C_Crawford, Sione

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

CDA Foundation - Using the Netflix Model to Eliminate HCV_Razavi, Homie

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

The UN Group of Friends to Eliminate Hepatitis_Ali, Nida

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

Short Talk: Cabotegravir/Rilpivirine Failures Despite Adherence - Jose Castillo-Mancilla, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Short Talk: Islatravir Toxicity - Charles Flexner, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Point of Care Tests for Drug Level Testing: Where Are We? - Paul K. Drain, MD, MPH, FIDSA

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Strategies to Improve Delivery to Reservoirs as Targets for Long-Acting Antivirals - Adeniyi Olagunju, BPharm, MRes, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Multipurpose Prevention Technologies (MPTs) For Prevention of HIV and Pregnancy - Sharon L. Hillier, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Pharmacokinetics of mAbs in Prevention, Treatment and Cure of Viral Infections -Edmund Capparelli, PharmD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Optimization of Pharmacology Studies and DDIs in Pregnant and Lactating Individuals -Angela Colbers, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Pharmacology Pearls for Managing Absorption and Swallowing Difficulties - Saye Khoo, MD, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Age-Related Changes in Pharmacokinetics and Pharmacodynamics - Catia Marzolini, PharmD, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

The Non-adherent Patient: A Good or Bad Candidate for CAB+RPV? - Jose Castillo-Mancilla, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Long-acting Cabotegravir for Treatment and Prevention - M. Boffito, MD, PhD, FRCP

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Long-acting Cabotegravir for Treatment and Prevention: When Are You Protected? - M. Boffito, MD, PhD, FRCP

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

What’s on the Horizon for Direct Acting Antivirals for Hepatitis B? - Jennifer Kiser, PharmD, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022